{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T11:10:56Z","timestamp":1785409856190,"version":"3.56.0"},"reference-count":97,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2024,4,10]],"date-time":"2024-04-10T00:00:00Z","timestamp":1712707200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Department of Internal Medicine and Therapeutics","award":["FRG2019ASSEGNI_DMC51"],"award-info":[{"award-number":["FRG2019ASSEGNI_DMC51"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Venetoclax is a Bcl-2 homology domain 3 (BH3) mimetic currently approved for the treatment of chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML) that has proven to be highly effective in reinstating apoptosis in leukemic cells through the highly selective inhibition of the anti-apoptotic protein B-cell lymphoma-2 (Bcl-2). Clinically, venetoclax has provided lasting remissions through the inhibition of CLL and AML blasts. However, this activity has often come at the cost of grade III\/IV neutropenia due to hematopoietic cells\u2019 dependence on Bcl-2 for survival. As life-threatening infections are an important complication in these patients, an effective management of neutropenia is indispensable to maximize patient outcomes. While there is general consensus over dose reduction and scheduling modifications to minimize the risk of neutropenia, the impact of these modifications on survival is uncertain. Moreover, guidelines do not yet adequately account for patient-specific and disease-specific risk factors that may predict toxicity, or the role combination treatment plays in exacerbating neutropenia. The objective of this review is to discuss the venetoclax-induced mechanism of hematological toxicity, the potential predictive risk factors that affect patient vulnerability to neutropenia, and the current consensus on practices for management of neutropenia.<\/jats:p>","DOI":"10.3390\/ph17040484","type":"journal-article","created":{"date-parts":[[2024,4,11]],"date-time":"2024-04-11T03:29:04Z","timestamp":1712806144000},"page":"484","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Venetoclax-Related Neutropenia in Leukemic Patients: A Comprehensive Review of the Underlying Causes, Risk Factors, and Management"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0103-1493","authenticated-orcid":false,"given":"Laura Giuseppina","family":"Di Pasqua","sequence":"first","affiliation":[{"name":"Department of Internal Medicine and Therapeutics, University of Pavia, 27100 Pavia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murwan Mahmoud","family":"Abdallah","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Therapeutics, University of Pavia, 27100 Pavia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fausto","family":"Feletti","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Therapeutics, University of Pavia, 27100 Pavia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2464-6127","authenticated-orcid":false,"given":"Mariapia","family":"Vairetti","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Therapeutics, University of Pavia, 27100 Pavia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2337-2897","authenticated-orcid":false,"given":"Andrea","family":"Ferrigno","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Therapeutics, University of Pavia, 27100 Pavia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,4,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Shimada, A. (2019). Hematological Malignancies and Molecular Targeting Therapy. Eur. J. Pharmacol., 862.","DOI":"10.1016\/j.ejphar.2019.172641"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"i3","DOI":"10.1093\/annonc\/mdl443","article-title":"Epidemiology of Hematological Malignancies","volume":"18","author":"Bordoni","year":"2007","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21654","article-title":"Cancer Statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA A Cancer J. Clin."},{"key":"ref_4","unstructured":"(2023, July 27). Australian Institute of Health and Welfare Cancer Data in Australia, About-Australian Institute of Health and Welfare, Available online: https:\/\/www.aihw.gov.au\/reports\/cancer\/cancer-data-in-australia\/contents\/about."},{"key":"ref_5","unstructured":"(2023, July 27). National Cancer Institute Surveillance, Epidemiology and End Results Program, Available online: https:\/\/seer.cancer.gov\/statistics-network\/explorer\/application.html?site=96&data_type=4&graph_type=2&compareBy=sex&chk_sex_1=1&relative_survival_interval=5&race=1&age_range=1&hdn_stage=101&advopt_precision=1&advopt_show_ci=on&hdn_view=0&advopt_show_apc=on&advopt_display=1#resultsRegion0."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1182\/asheducation-2006.1.279","article-title":"New Prognostic Markers in CLL","volume":"1","author":"Montserrat","year":"2006","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1182\/asheducation-2016.1.149","article-title":"Prognostication of Chronic Lymphocytic Leukemia in the Era of New Agents","volume":"2016","author":"Eichhorst","year":"2016","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.critrevonc.2007.04.008","article-title":"Chronic Lymphocytic Leukemia","volume":"64","author":"Ghia","year":"2007","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"140","DOI":"10.3324\/haematol.2013.086066","article-title":"Chronic Lymphocytic Leukemia in Young (\u226455 Years) Patients: A Comprehensive Analysis of Prognostic Factors and Outcomes","volume":"99","author":"Parikh","year":"2014","journal-title":"Haematologica"},{"key":"ref_10","first-page":"107","article-title":"Chronic Lymphocytic Leukemia in the Young Patient","volume":"25","author":"Lerner","year":"1998","journal-title":"Semin. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1289\/ehp.7433","article-title":"Ionizing Radiation and Chronic Lymphocytic Leukemia","volume":"113","author":"Richardson","year":"2005","journal-title":"Environ. Health Perspect."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e441","DOI":"10.1038\/bcj.2016.50","article-title":"Acute Myeloid Leukemia: A Comprehensive Review and 2016 Update","volume":"6","year":"2016","journal-title":"Blood Cancer J."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"(2013). Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia. N. Engl. J. Med., 368, 2059\u20132074.","DOI":"10.1056\/NEJMoa1301689"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1182\/blood-2002-02-0492","article-title":"The Roles of FLT3 in Hematopoiesis and Leukemia","volume":"100","author":"Gilliland","year":"2002","journal-title":"Blood"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1158\/2159-8290.CD-22-0332","article-title":"TP53-Mutated Myelodysplastic Syndrome and Acute Myeloid Leukemia: Biology, Current Therapy, and Future Directions","volume":"12","author":"Daver","year":"2022","journal-title":"Cancer Discov."},{"key":"ref_16","first-page":"28","article-title":"Prognostic Relevance of NPM1, CEBPA, and FLT3 Mutations in Cytogenetically Normal Adult AML Patients","volume":"13","author":"Ningombam","year":"2023","journal-title":"Am. J. Blood Res."},{"key":"ref_17","first-page":"e30449","article-title":"Clinical and Etiological Profiles of Patients With Pancytopenia in a Tertiary Care Hospital","volume":"14","author":"Gajbhiye","year":"2022","journal-title":"Cureus"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and Management of AML in Adults: 2022 Recommendations from an International Expert Panel on Behalf of the ELN","volume":"140","author":"Wei","year":"2022","journal-title":"Blood"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1056\/NEJMoa1815281","article-title":"Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions","volume":"380","author":"Fischer","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1056\/NEJMoa1713976","article-title":"Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia","volume":"378","author":"Seymour","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1182\/blood.2020004856","article-title":"Venetoclax plus LDAC for Newly Diagnosed AML Ineligible for Intensive Chemotherapy: A Phase 3 Randomized Placebo-Controlled Trial","volume":"135","author":"Wei","year":"2020","journal-title":"Blood"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1080\/17512433.2021.2008239","article-title":"Keeping up with Venetoclax for Leukemic Malignancies: Key Findings, Optimal Regimens, and Clinical Considerations","volume":"14","author":"Siddiqui","year":"2021","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s13027-021-00413-z","article-title":"Infectious Diseases as a Cause of Death among Cancer Patients: A Trend Analysis and Population-Based Study of Outcome in the United States Based on the Surveillance, Epidemiology, and End Results Database","volume":"16","author":"Elhadi","year":"2021","journal-title":"Infect. Agent. Cancer"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/bjh.18051","article-title":"Characterisation of Infections in Patients with Acute Myeloid Leukaemia Receiving Venetoclax and a Hypomethylating Agent","volume":"197","author":"On","year":"2022","journal-title":"Br. J. Haematol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/335440a0","article-title":"Bcl-2 Gene Promotes Haemopoietic Cell Survival and Cooperates with c-Myc to Immortalize Pre-B Cells","volume":"335","author":"Vaux","year":"1988","journal-title":"Nature"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1126\/science.281.5381.1322","article-title":"The Bcl-2 Protein Family: Arbiters of Cell Survival","volume":"281","author":"Adams","year":"1998","journal-title":"Science"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.molcel.2004.12.030","article-title":"Differential Targeting of Prosurvival Bcl-2 Proteins by Their BH3-Only Ligands Allows Complementary Apoptotic Function","volume":"17","author":"Chen","year":"2005","journal-title":"Mol. Cell"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1101\/gad.1304105","article-title":"Proapoptotic Bak Is Sequestered by Mcl-1 and Bcl-xL, but Not Bcl-2, until Displaced by BH3-Only Proteins","volume":"19","author":"Willis","year":"2005","journal-title":"Genes. Dev."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/nrm3722","article-title":"Control of Apoptosis by the BCL-2 Protein Family: Implications for Physiology and Therapy","volume":"15","author":"Czabotar","year":"2014","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S1535-6108(02)00128-9","article-title":"BH3 Domains: Intracellular Death-Ligands Critical for Initiating Apoptosis","volume":"2","author":"Chittenden","year":"2002","journal-title":"Cancer Cell"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"985363","DOI":"10.3389\/fonc.2022.985363","article-title":"The Role of BCL-2 Family Proteins in Regulating Apoptosis and Cancer Therapy","volume":"12","author":"Qian","year":"2022","journal-title":"Front. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/nrd.2016.253","article-title":"From Basic Apoptosis Discoveries to Advanced Selective BCL-2 Family Inhibitors","volume":"16","author":"Ashkenazi","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s11899-017-0359-0","article-title":"The Development and Current Use of BCL-2 Inhibitors for the Treatment of Chronic Lymphocytic Leukemia","volume":"12","author":"Lampson","year":"2017","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"7697","DOI":"10.1200\/JCO.2005.02.4364","article-title":"Phase I to II Multicenter Study of Oblimersen Sodium, a Bcl-2 Antisense Oligonucleotide, in Patients with Advanced Chronic Lymphocytic Leukemia","volume":"23","author":"Cunningham","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1182\/blood-2008-02-137943","article-title":"Phase I Study of Obatoclax Mesylate (GX15-070), a Small Molecule Pan-Bcl-2 Family Antagonist, in Patients with Advanced Chronic Lymphocytic Leukemia","volume":"113","author":"Claxton","year":"2009","journal-title":"Blood"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1200\/JCO.2011.34.7898","article-title":"Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients with Relapsed or Refractory Disease","volume":"30","author":"Roberts","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1038\/sj.cdd.4402081","article-title":"Bcl-2 Family Proteins Are Essential for Platelet Survival","volume":"14","author":"Zhang","year":"2007","journal-title":"Cell Death Differ."},{"key":"ref_39","unstructured":"(2023, October 16). Center for Drug Evaluation and Research FDA Grants Regular Approval to Venetoclax in Combination for Untreated Acute Myeloid Leukemia, Available online: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-regular-approval-venetoclax-combination-untreated-acute-myeloid-leukemia."},{"key":"ref_40","unstructured":"(2023, October 16). Center for Drug Evaluation and Research FDA Approves Venetoclax for CLL and SLL, Available online: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-venetoclax-cll-and-sll."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nm.3048","article-title":"ABT-199, a Potent and Selective BCL-2 Inhibitor, Achieves Antitumor Activity While Sparing Platelets","volume":"19","author":"Souers","year":"2013","journal-title":"Nat. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1513257","article-title":"Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia","volume":"374","author":"Roberts","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1111\/bjh.13487","article-title":"Phase 1 Study of the Safety, Pharmacokinetics, and Antitumour Activity of the BCL2 Inhibitor Navitoclax in Combination with Rituximab in Patients with Relapsed or Refractory CD20+ Lymphoid Malignancies","volume":"170","author":"Roberts","year":"2015","journal-title":"Br. J. Haematol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S1470-2045(17)30012-8","article-title":"Venetoclax plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukaemia: A Phase 1b Study","volume":"18","author":"Seymour","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1182\/blood.2020009578","article-title":"Efficacy of Venetoclax plus Rituximab for Relapsed CLL: 5-Year Follow-up of Continuous or Limited- Duration Therapy","volume":"138","author":"Ma","year":"2021","journal-title":"Blood"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/j.1365-2141.2011.09000.x","article-title":"Chronic Lymphocytic Leukaemia with 17p Deletion: A Retrospective Analysis of Prognostic Factors and Therapy Results","volume":"157","author":"Delgado","year":"2012","journal-title":"Br. J. Haematol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1001\/jamaoncol.2014.218","article-title":"Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients with Chronic Lymphocytic Leukemia","volume":"1","author":"Maddocks","year":"2015","journal-title":"JAMA Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa1315226","article-title":"Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia","volume":"370","author":"Furman","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1200\/JCO.2017.76.6840","article-title":"Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial","volume":"36","author":"Stilgenbauer","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/S1470-2045(16)30019-5","article-title":"Venetoclax in Relapsed or Refractory Chronic Lymphocytic Leukaemia with 17p Deletion: A Multicentre, Open-Label, Phase 2 Study","volume":"17","author":"Stilgenbauer","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1200\/JCO.18.01580","article-title":"Fixed Duration of Venetoclax-Rituximab in Relapsed\/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study","volume":"37","author":"Kater","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"4042","DOI":"10.1200\/JCO.20.00948","article-title":"Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study","volume":"38","author":"Kater","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1182\/blood-2019-01-896290","article-title":"Phase 1b Study of Venetoclax-Obinutuzumab in Previously Untreated and Relapsed\/Refractory Chronic Lymphocytic Leukemia","volume":"133","author":"Flinn","year":"2019","journal-title":"Blood"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1182\/blood-2017-06-788133","article-title":"Venetoclax for Patients with Chronic Lymphocytic Leukemia Who Progressed during or after Idelalisib Therapy","volume":"131","author":"Coutre","year":"2018","journal-title":"Blood"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S1470-2045(17)30909-9","article-title":"Venetoclax for Chronic Lymphocytic Leukaemia Progressing after Ibrutinib: An Interim Analysis of a Multicentre, Open-Label, Phase 2 Trial","volume":"19","author":"Jones","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1080\/10428194.2021.1986217","article-title":"Impact of Venetoclax Monotherapy on the Quality of Life of Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia: Results from the Phase 3b VENICE II Trial","volume":"63","author":"Cochrane","year":"2022","journal-title":"Leuk. Lymphoma"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1182\/blood-2019-125825","article-title":"Quantitative Analysis of Minimal Residual Disease (MRD) Shows High Rates of Undetectable MRD after Fixed-Duration Chemotherapy-Free Treatment and Serves As Surrogate Marker for Progression-Free Survival: A Prospective Analysis of the Randomized CLL14 Trial","volume":"134","author":"Fischer","year":"2019","journal-title":"Blood"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1016\/S1470-2045(20)30443-5","article-title":"Venetoclax plus Obinutuzumab versus Chlorambucil plus Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukaemia (CLL14): Follow-up Results from a Multicentre, Open-Label, Randomised, Phase 3 Trial","volume":"21","author":"Zhang","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1056\/NEJMoa2213093","article-title":"First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia","volume":"388","author":"Eichhorst","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1158\/2159-8290.CD-16-0313","article-title":"Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia","volume":"6","author":"Konopleva","year":"2016","journal-title":"Cancer Discov."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","article-title":"Venetoclax Combined with Decitabine or Azacitidine in Treatment-Naive, Elderly Patients with Acute Myeloid Leukemia","volume":"133","author":"DiNardo","year":"2019","journal-title":"Blood"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1200\/JCO.18.01600","article-title":"Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib\/II Study","volume":"37","author":"Wei","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/s41408-021-00555-8","article-title":"6-Month Follow-up of VIALE-C Demonstrates Improved and Durable Efficacy in Patients with Untreated AML Ineligible for Intensive Chemotherapy (141\/150)","volume":"11","author":"Wei","year":"2021","journal-title":"Blood Cancer J."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1007\/s11912-022-01299-9","article-title":"Older Patients with Acute Myeloid Leukemia Deserve Individualized Treatment","volume":"24","author":"Ossenkoppele","year":"2022","journal-title":"Curr. Oncol. Rep."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1007\/s00277-023-05529-3","article-title":"Myeloid Sarcoma of the Urinary Bladder as the Presenting Feature of Secondary Acute Myeloid Leukemia, Successfully Treated with Venetoclax and Azacitidine","volume":"103","author":"Lucijanic","year":"2024","journal-title":"Ann. Hematol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"3506","DOI":"10.1200\/JCO.20.00572","article-title":"Chemotherapy and Venetoclax in Elderly Acute Myeloid Leukemia Trial (CAVEAT): A Phase Ib Dose-Escalation Study of Venetoclax Combined With Modified Intensive Chemotherapy","volume":"38","author":"Chua","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"400","DOI":"10.6004\/jadpro.2022.13.4.4","article-title":"Practical Management of the Venetoclax-Treated Patient in Chronic Lymphocytic Leukemia and Acute Myeloid Leukemia","volume":"13","author":"Waggoner","year":"2022","journal-title":"J. Adv. Pract. Oncol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"e3240","DOI":"10.1097\/MD.0000000000003240","article-title":"Prognostic Value of Chemotherapy-Induced Neutropenia at the First Cycle in Invasive Breast Cancer","volume":"95","author":"Ma","year":"2016","journal-title":"Medicine"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.critrevonc.2017.11.005","article-title":"Impact of Chemotherapy-Induced Neutropenia (CIN) and Febrile Neutropenia (FN) on Cancer Treatment Outcomes: An Overview about Well-Established and Recently Emerging Clinical Data","volume":"120","author":"Lalami","year":"2017","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"279ra40","DOI":"10.1126\/scitranslmed.aaa4642","article-title":"Exploiting Selective BCL-2 Family Inhibitors to Dissect Cell Survival Dependencies and Define Improved Strategies for Cancer Therapy","volume":"7","author":"Leverson","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"e1505","DOI":"10.1002\/cnr2.1505","article-title":"Evaluation and Associated Risk Factors for Neutropenia with Venetoclax and Obinutuzumab in the Treatment of Chronic Lymphocytic Leukemia","volume":"5","author":"Samuels","year":"2022","journal-title":"Cancer Rep."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"E416","DOI":"10.1002\/ajh.26692","article-title":"Postremission Cytopenia Management in Patients with Acute Myeloid Leukemia Treated with Venetoclax and Azacitidine in VIALE-A","volume":"97","author":"Pratz","year":"2022","journal-title":"Am. J. Hematol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1182\/bloodadvances.2023011964","article-title":"Infectious Complications of Venetoclax Treatment of Hematologic Malignancies: A Systematic Review and Meta-Analysis","volume":"8","author":"Prosty","year":"2023","journal-title":"Blood Adv."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s00277-023-05102-y","article-title":"Shorter Duration of Venetoclax Administration to 14 Days Has Same Efficacy and Better Safety Profile in Treatment of Acute Myeloid Leukemia","volume":"102","author":"Aiba","year":"2023","journal-title":"Ann. Hematol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"562558","DOI":"10.3389\/fonc.2020.562558","article-title":"Venetoclax-Based Combinations in Acute Myeloid Leukemia: Current Evidence and Future Directions","volume":"10","author":"Samra","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"20406207221127550","DOI":"10.1177\/20406207221127550","article-title":"Coexisting Conditions and Concomitant Medications Do Not Affect Venetoclax Management and Survival in Chronic Lymphocytic Leukemia","volume":"13","author":"Frustaci","year":"2022","journal-title":"Ther. Adv. Hematol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"380","DOI":"10.20517\/cdr.2021.125","article-title":"Venetoclax Resistance: Mechanistic Insights and Future Strategies","volume":"5","author":"Ong","year":"2022","journal-title":"Cancer Drug Resist."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1182\/blood.2019003988","article-title":"Molecular Patterns of Response and Treatment Failure after Frontline Venetoclax Combinations in Older Patients with AML","volume":"135","author":"DiNardo","year":"2020","journal-title":"Blood"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1158\/2159-8290.CD-18-1119","article-title":"Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia","volume":"9","author":"Blombery","year":"2019","journal-title":"Cancer Discov."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1005659","DOI":"10.3389\/fonc.2022.1005659","article-title":"Mechanisms of Venetoclax Resistance and Solutions","volume":"12","author":"Liu","year":"2022","journal-title":"Front. Oncol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1182\/blood-2021-145217","article-title":"Phase II Study of Venetoclax in Combination with Obinutuzumab and Bendamustine in Patients with High Tumor Burden Follicular Lymphoma As Front Line Therapy (PrECOG 0403)","volume":"138","author":"Portell","year":"2021","journal-title":"Blood"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/S1470-2045(20)30525-8","article-title":"Venetoclax or Placebo in Combination with Bortezomib and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma (BELLINI): A Randomised, Double-Blind, Multicentre, Phase 3 Trial","volume":"21","author":"Kumar","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s00520-003-0442-z","article-title":"Development and Validation of a Patient-Specific Predictive Instrument for the Need for Dose Reduction in Chemotherapy for Breast Cancer: A Potential Decision Aid for the Use of Myeloid Growth Factors","volume":"11","author":"Savvides","year":"2003","journal-title":"Support. Care Cancer"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1002\/ajh.23661","article-title":"Prediction of Adverse Events during Intensive Induction Chemotherapy for Acute Myeloid Leukemia or High-Grade Myelodysplastic Syndromes","volume":"89","author":"Buckley","year":"2014","journal-title":"Am. J. Hematol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1002\/ajh.26601","article-title":"Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed acute myeloid leukemia","volume":"97","author":"DiNardo","year":"2022","journal-title":"Am. J. Hematol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1097\/PPO.0000000000000567","article-title":"How We Incorporate Venetoclax in Treatment Regimens for Acute Myeloid Leukemia","volume":"28","author":"Maiti","year":"2022","journal-title":"Cancer J."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1208\/s12249-021-01968-1","article-title":"Development and Characterization of Venetoclax Nanocrystals for Oral Bioavailability Enhancement","volume":"22","author":"Kala","year":"2021","journal-title":"AAPS PharmSciTech"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1002\/jcph.821","article-title":"Pharmacokinetics of Venetoclax, a Novel BCL-2 Inhibitor, in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Non-Hodgkin Lymphoma","volume":"57","author":"Salem","year":"2017","journal-title":"J. Clin. Pharmacol."},{"key":"ref_89","first-page":"e8908","article-title":"Venetoclax in the Treatment of Chronic Lymphocytic Leukemia: Evidence, Expectations, and Future Prospects","volume":"12","author":"Tariq","year":"2020","journal-title":"Cureus"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1208\/s12248-016-9927-9","article-title":"Clinical Predictors of Venetoclax Pharmacokinetics in Chronic Lymphocytic Leukemia and Non-Hodgkin\u2019s Lymphoma Patients: A Pooled Population Pharmacokinetic Analysis","volume":"18","author":"Jones","year":"2016","journal-title":"AAPS J."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.clinthera.2017.01.003","article-title":"Management of Venetoclax-Posaconazole Interaction in Acute Myeloid Leukemia Patients: Evaluation of Dose Adjustments","volume":"39","author":"Agarwal","year":"2017","journal-title":"Clin. Ther."},{"key":"ref_92","unstructured":"(2024, April 08). Venetoclax FDA Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/208573s013lbl.pdf."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1002\/jcph.858","article-title":"Quantitative Prediction of the Effect of CYP3A Inhibitors and Inducers on Venetoclax Pharmacokinetics Using a Physiologically Based Pharmacokinetic Model","volume":"57","author":"Freise","year":"2017","journal-title":"J. Clin. Pharmacol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"2040620719882822","DOI":"10.1177\/2040620719882822","article-title":"Venetoclax for the Treatment of Newly Diagnosed Acute Myeloid Leukemia in Patients Who Are Ineligible for Intensive Chemotherapy","volume":"10","author":"DiNardo","year":"2019","journal-title":"Ther. Adv. Hematol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1097\/CAD.0000000000001541","article-title":"Venetoclax Dose Adjustment Due to Drug-Drug Interactions: A Case Report and Literature Review","volume":"35","author":"Fan","year":"2024","journal-title":"Anticancer. Drugs"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1080\/00498254.2017.1381779","article-title":"Clinical Evaluation of P-Glycoprotein Inhibition by Venetoclax: A Drug Interaction Study with Digoxin","volume":"48","author":"Chiney","year":"2018","journal-title":"Xenobiotica"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1007\/s12325-018-0793-y","article-title":"Effect of Azithromycin on Venetoclax Pharmacokinetics in Healthy Volunteers: Implications for Dosing Venetoclax with P-Gp Inhibitors","volume":"35","author":"Agarwal","year":"2018","journal-title":"Adv. Ther."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/17\/4\/484\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:25:58Z","timestamp":1760106358000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/17\/4\/484"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,10]]},"references-count":97,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,4]]}},"alternative-id":["ph17040484"],"URL":"https:\/\/doi.org\/10.3390\/ph17040484","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,10]]}}}